Search
Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month
He discusses learnings from the company's previous data release in early June and how he believes the new data presented gives investors a fuller picture of the efficacy and safety profile of the therapy. He discusses next steps from a regulatory and business standpoint, clarifies a key point of investor confusion, and also provides an update on the company's Crohn's trial.
Jun 30
SF Healthcare Week: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year
He discusses the company's accomplishments to date, and highlights learnings about the mechanism and important data in 2026 in the maintenance setting for UC and Crohn's later this year.
Jan 11
BIO-Europe 2025: Abivax CEO Marc de Garidel discusses physician and payor feedback after obefazimod's phase 3 UC induction readouts, and next steps regarding maintenance and Crohn's
He describes the mechanism of the therapy, as well the data and commercial landscape for UC. Plus, how he thinks about combos and business development. Coverage brought to you by:
Nov 3, 2025
Abivax CEO Marc de Garidel discusses Obefazimod's phase 3 trial result in ulcerative colitis, and what is next for the company
He covers the mechanism of action, this week's efficacy and safety data, what it might mean for the maintenance trial that will read out...
Jul 24, 2025
.png){kind=logo}